- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Angus Worthing: The Benefits of Biosimilars
Angus Worthing, MD, FACR, FACP, discusses the benefits of biosimilar medicines.
Transcript:
What benefits do biosimilars offer to providers and to the healthcare system?
Biologic drugs have really revolutionized the practice [and] treatment of rheumatoid arthritis, and other autoimmune diseases, but that has come at a tremendous cost and oftentimes the price is a lack of access to drugs. So, it’s one of the things that gets me up out of bed in the morning, and what I really like my job for, is that I can see people, and diagnose them, and put a treatment plan in place that’s going to get them back to work and reduce their aching joints. But, it’s heartbreaking when people can’t get access to the drugs because they’re too expensive. The best thing that biosimilars give to providers, and also to patients, is the promise of increased access to care, so that everybody who needs one of these drugs can get on it, afford it, and have it also be affordable for society at large—that’s the benefit of biosimilars. In short, that’s the benefit of biosimilars.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
